iBioLaunch System Achieves Tech Transfer Milestone

iBio, Inc. has achieved a critical technology transfer milestone verified by an independent third party lab. The validation milestone confirmed that the iBioLaunch system can be used by third parties to replicate production of commercial yields of targeted biopharmaceuticals, including vaccines and therapeutics, without assistance from iBio.
 
“In light of our recently announced commercial collaborations, this is an important demonstration that our technology can be readily utilized by others for commercialization of their respective products,” said Robert Erwin, iBio’s president. “To prove that, we designed the milestone to require the third party lab to implement the iBioLaunch system without assistance from iBio.”
 
The company can also assist with implementing standard operating procedures for the technology and provides quality assurance and quality control documentation and procedures for product and site-specific implementation. iBio also provides staff training in collaboration with the Fraunhofer USA Center for Molecular Biotechnology, which operates a cGMP pilot facility in Delaware based on the iBioLaunch platform.